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ABSTRACT
Recent  recommendations  emphasize  the  need  to  assess  kidney  function  using
creatinine- based  predictive  equations,  in order  to  optimize  the  care  of  patients  with
chronic  kidney disease  (CKD). The most  widely used  equations  are  the  Cockcroft- Gault
(CG) and  the  simplified  MDRD formulas.  However,  they  still  need  to  be  validated  in
large  samples  of  subjects,  including  large  non-US cohorts.  We  compared  renal
clearance  of 51Cr-EDTA with  glomerular  filtration  rate  (GFR) estimated  using either  the
Cockcroft  - Gault  equation  or  the  MDRD formula  in a  cohort  of 2,095  adult  Europeans
(863  female  and  1,232  male,  median  age  53.2  years,  median  measured  GFR 59.8
mL/min/1.73m 2).  When the  entire  study population  was considered,  the  CG and  MDRD
equations  showed  very  limited  bias.  They  overestimated  measured  GFR by  1.94
mL/min/1.73m 2 and  underestimated  it  by  0.99  mL/min/1.73m 2,  respectively.
However,  analysis  of  subgroups  defined  by age,  gender,  BMI, and  GFR level  showed
that  the  biases  of  the  two  formulas  could  be  much  larger  in  selected  populations.
Furthermore,  analysis  of  the  standard  deviation  of  the  mean  difference  between
estimated  and  measured  GFR showed  that  both  formulas  lacked  precision;  the  CG
formula  being  less  precise  than  the  MDRD one  in  most  cases.  In  the  whole  study
population,  the  standard  deviation  was 15.1  mL/min/1.73m 2 and  13.5  mL/min/1.73m 2
for the  CG and  MDRD formulas,  respectively.  Finally,  29.2% and  32.4% of subjects  were
misclassified  when  the  CG or  MDRD formulas  where  used  to  categorize  subjects
according to  the  K/DOQI CKD classification,  respectively.
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INTRODUCTION:
The prevalent and incident rates of end stage renal disease (ESRD) are continuously increasing in
all Western countries. Data from the US Renal Data System predict that the number of patients
registered with ESRD in 1997 will have doubled in 2010, leading to approximately 700 000
patients with ESRD and 2.2 million patients in 2030 (32), and similar trends are anticipated in
other countries  (27, 23, 14, 4, 22). In order to level off these incident rates, various initiatives,
such as the Kidney Disease Outcomes Quality Initiative (K/DOQI),  have provided physicians
with  guidelines  to  optimize  the  care  of  patients  with  chronic  kidney  disease  (CKD).  These
guidelines emphasize the need to assess kidney function using predictive equations rather than
serum creatinine alone (25). However, they also highlight the fact that these equations still need
to be validated in large samples of subjects, and in particular that they should be tested in non-US
populations  and  in  individuals  with  mild  decrease  in  kidney  function  or  normal  GFR  (25).
Validation of the predictive formulas is also particularly important for patients aged 65 and older,
who have by far the highest incident rates of ESRD (27, 23, 14, 4, 22). 
The  formulas  that  are  most  widely  used  to  estimate  kidney  function,  and  that  are
recommended  in  adults  by the  K/DOQI guidelines  (25),  are  the  Cockcroft- Gault  (CG)
formula  (8) and  the  recently  developed  (19) and  later  simplified  (21) Modification  of
Diet  in  Renal  Disease  (MDRD) formula.  The  CG formula  is  an  estimate  of  creatinine
clearance  originally developed  in a  population  of 236 Canadian  patients,  209 of which
were  males.  The  MDRD formulas  have  been  developed  as  an  estimation  of  125I-
Iothalamate  renal  clearance- based  GFR measurement  in a population  of 1,628 patients
with  previously diagnosed  Chronic Kidney Disease  (27,  23,  14,  4,  22).  The mean  GFR in
this  population  was 39.8  ± 21.2  mL/min/1.73m2  and  the  mean  age  of the  cohort  was
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50.6  ± 12.7  years.  
The K/DOQI CKD guidelines  have  established  a five-stage  classification  of patients  with
CKD that  is  based  solely  on  kidney  function.  These  stages  are  defined  by  GFR ³ 90
mL/min/1.73m 2 (stage  1),  60 to  89 mL/min/1.73m 2 (stage  2),  30 to  59 mL/min/1.73m 2
(stage  3),  15 to  29 mL/min/1.73m 2 (stage  4),  and  <15 mL/min/1.73m 2 (stage  5),  (25).
The  guidelines  state  that  the  stage  of  kidney  disease  should  be  determined  for  each
CKD patient,  and  that  a clinical  action  plan  should  be  developed  based  on the  stage  of
disease  (25).  Thus,  inaccurate  estimation  of  kidney  function  may  be  responsible  for
misclassification  of  some  patients  and  lead  to  inappropriate  evaluation  or  treatment
of these  patients  (13).  However,  so far,  few studies  have  assessed  the  applicability  of
the  MDRD and  CG formulas  to  large  cohorts  of  subjects  with  wide  ranges  of  renal
function.  One study  compared  various  formulas  with  125I-iothalamate  GFR, in a  cohort
of  1,703  African  Americans  with  presumed  hypertensive  nephrosclerosis  and  mean
serum  creatinine  levels  of  1.85  ± 0.88  mg/dL  (27,  23,  14,  4,  22).  All other  studies
focused  on much  smaller  cohorts  of subjects  with  or  without  CKD (27,  23,  14,  4,  22).
Furthermore,  with  one  exception  (14),  no particular  attention  was paid  to  calibration
of  serum  creatinine  measurements,  while  this  has  been  shown  to  be  of  critical
importance  for subjects  with  normal  or near  normal  serum  creatinine  values  (10,  9).
In  this  study,  we  compare  renal  clearance  of  51Cr-EDTA (measured  GFR) with  GFR
estimated  by the  CG formula  (CG GFR) or  the  MDRD equation  (MDRD GFR) in a  cohort
of  2,095  European  subjects.  Our  findings  support  the  preferential  use  of  the  MDRD
formula,  but  raise  caution  regarding  its  usage  in some  subgroups  of  subjects  such  as
young adults  with  normal  renal  function  or stage  2 CKD or underweight  subjects.
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MATERIALS AND METHODS
Patient  selection
Records  of  all  patients  referred  to  our  Department  of  Physiology  between  January
1990  and  April  2004  in  order  to  perform  GFR measurements  were  retrospectively
reviewed.  For  patients  who  had  more  than  one  GFR measurement,  only the  first  one
was  considered.  Renal  transplant  patients  and  subjects  under  18  years  of  age  were
excluded.  Among the  remaining 2,178 independent  patients,  only 83 were  black.  Since
ethnicity  is  one  of  the  determinants  of  the  MDRD equation,  we  decided  to  exclude
black  patients  and  restrict  the  analysis to  the  2,095  non-black  individuals,  in order  to
ensure  statistical  relevance  of  the  study.  Among them,  1,933  had  CKD and  162 were
healthy  potential  kidney donors.
GFR measurements
Renal  clearance  of  51Cr-EDTA was  determined  as  previously described  (27,  23,  14,  4,
22).  Briefly,  3.5  MBq of  51Cr-EDTA (Amersham  Health  SA) were  injected  intravenously
as  a  single  bolus.  The  injected  dose  was  reduced  to  1.8  MBq in  patients  with  an
estimated  GFR derived  from  the  CG formula  of  less  than  30  mL/min  and  in  case  of
body weight  lower  than  40 kg.  After  allowing one  hour  for  distribution  of the  tracer  in
the  extracellular  fluid,  urine  was  collected  and  discarded.  Then,  average  renal  51Cr-
EDTA clearance  was  determined  on five  consecutive  30-min  clearance  periods.  Blood
was drawn  at  the  midpoint  of each  clearance  period  and  up to  300 min after  injection.
The radioactivity  measurements  in 1-ml plasma  and  urine  samples  were  carried  out  on
a  3-inch  crystal  gamma- ray  well  counter  (Packard  Cobra,  Alberta,  MN). When  timed
6
H
AL author m
anuscript    inserm
-00149221, version 1
urine  samples  could  not  be  obtained,  plasma  clearance  of  51Cr-EDTA was  calculated
according  to  a  simplified  method  described  by  Brochner- Mortensen  (5).  This  was
performed  in 219 patients  (10.5  %). In our  hands,  the  coefficients  of variation  of renal
clearance  of  51Cr-EDTA and  plasma  clearance  of  51Cr-EDTA were  8.4  ± 5.0  % and  9.0  ±
5.3  %, respectively,  while  the  coefficient  of variation  of inulin clearance  was 9.1  ± 6.3
% in the  same  22 patients.  When compared  to  inulin renal  clearance  the  mean  bias  of
EDTA renal  clearance  was  4.0  ± 4.9  mL/min/1.73m 2 (Froissart  et  al.  manuscript  in
preparation).
Creatinine  assay
All creatinine  measurements  were  performed  in  the  same  laboratory.  Blood  samples
were  obtained  simultaneously  with  the  GFR measurement.  A modified  kinetic  Jaffé
colorimetric  method  was  used  with  a  Bayer  RA-XT and  a  Konelab  20 analyzer.  A five
point  calibration  was  applied  in  each  assay.  Prior  to  measurement,  ultrafiltration  of
plasma  through  a  20  kDa  cut- off  membrane  (MPS-1,  Amicon,  Beverly,  MA) was
performed  in order  to  discard  chromogens  linked  to  albumin  and  other  heavy proteins.
In the  absence  of  an  international  standard  for  creatinine  assay,  the  linearity  of  the
measurements  was  verified  by  using  plasma  samples  from  normal  subjects  in  which
increasing  amounts  of  desiccated  creatinine  hydrochloride  (MW  149.6;  Sigma
Chemicals,  Perth,  Australia)  had  been  added.
Linear  regression  analysis showed  that  the  slope  of the  relationship  between  measured
and  expected  creatinine  concentrations  was1.008  ± 0.006  (95% confidence  interval
0.997  -  1.020)  and  that  the  Y-intercept  was  0.014  ± 0.013  (95% confidence  interval
-0.013  -  0.041),  (Figure  1).  Squared  Spearman  rank  coefficient  of  correlation  was
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0.998.  Internal  quality  controls  showed  a  coefficient  of  variation  of  2.3  % during  the
period.  An indirect  evaluation  of  the  stability  of the  measurement  was  obtained  from
the  ratiometric  expression  of MDRD/GFR values  over  time.  No clear  shift  was observed
during  the  entire  study  period,  supporting  the  absence  of  variation  in  creatinine
calibration  (data  not  shown).  Calibration  of our  creatinine  measurements  [HEGPcr.]  to
the  ones  of  the  MDRD laboratory  [MDRDcr.]  (Dr  F.  Van  Lente)  showed  a  linear
relationship  defined  by the  following equation  :
[MDRDcr.] = 1.151 x [HEGPcr.]  – 0.107
Thus for serum creatinine  ranging from 0.6 to  1.2  mg/dL,  the  difference  between  both
measurements  (MDRDcr. – HEGPcr.)  is comprised  between  -0.016 and  +0.074 mg/dL.
Creatinine  based  estimation  of  GFR
The two  formulas  that  we studied  in order  to  predict  GFR from serum  creatinine  were
the  one  proposed  by Cockcroft  and  Gault  (8):
CG GFR = [(140 - Age (yr))  x Weight  (kg) /  (7.2  x PCr (mg/dL)]  x (0.85  if Female)
and  the  simplified  form of the  MDRD formula  (21):
MDRD GFR = 186.3  x  PCr  (mg/dL) -1.154  x  Age  (yr) -0.203  x  (1.212  if  Black)  x  (0.742  if
Female);
Where  PCr is plasma  creatinine  concentration.
A correction  for  body surface  area  was necessary  for  CG formula.  This was  performed
using estimated  BSA according to  Du Bois (11):  
BSA = Weight  (kg)0.425 x Height  (m)0.725 x 0.20247 
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Statistical  analysis
Demographic  data  were  expressed  as  mean  ± standard  deviation  (SD) or  median  and
Interquartile  Range (IQR), as appropriate.  
Estimated  and  measured  GFR are  statistically  dependent  variables.  In  order  to
compare  the  creatinine- based  estimations  of  GFR with  the  renal  clearance  of  51Cr-
EDTA, we used  Bland and  Altman  recommendations  for such evaluations  (1).  The mean
difference  between  estimated  and  measured  GFR values  directly  estimates  the  global
bias.  The  width  of  the  standard  deviation  of the  mean  difference  is an  estimation  of
precision;  a large  width  meaning a low precision.
The  absolute  of  the  difference  between  estimated  and  measured  GFR was  used  to
estimate  the  accuracy  of  the  creatinine- based  formulas.  It  was  expressed  either  in
mL/min/1.73m 2 or  in  percentage  of  GFR values  and  was  represented  in  percentiles
(50 th ,  75th ,  and  90th),  allowing to  draw  absolute  and  relative  boundaries  for  the  lack of
accuracy.  The  accuracy  was  also  measured  as  the  percentage  of results  not  deviating
more  than  15,  30 and  50% from the  measured  GFR.
The  combined  root  mean  square  error  (CRMSE) was  examined.  CRMSE is calculated  as
the  square  root  of [(mean  difference  between  estimated  and  measured  GFR)2 + (SD of
the  difference) 2].  It measures  both  bias and  precision (27,  23,  14,  4,  22).
Statistical  analyses  were  performed  using Statview  5.0 software  (SAS, Cary,  NC)
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RESULTS
1.  Demographics and GFR distribution.
The main  characteristics  of the  study  population  are  shown in Table  1.  All 162 kidney
donors  were  under  65  years  of  age.  Measured  GFR values  were  equally  distributed
above  (1,044  subjects)  and  below (1,051  subjects)  60 mL/min/1.73m 2.  For subsequent
analyses,  the  study  population  was  divided  into  subgroups  according  to  gender,  age
(18 to  64 years  versus  65 years  or  older),  and/or  measured  GFR (³  60 mL/min/1.73m 2
versus < 60 mL/min/1.73m 2).  
Two-way  ANOVA test  showed  that  measured  GFR values  differed  with  respect  to
gender  and  age.  Females  had  higher  measured  GFR values  than  males  (65.8  ± 33.8
versus  57.9  ± 31.5  mL/min/1.73m 2,  p < 0.0001).  Subjects  65 years  or  older  had  lower
GFR values  than  younger  ones  (45.2  ± 24.3  versus  67.4  ± 33.4  mL/min/1.73m 2,  p  <
0.0001).  However  no significant  interaction  between  gender  and  age  was  observed  (p
= 0.2880).  
2.  Relationships  between  creatinine- based  estimations  of  GFR and  measured
GFR
The  relationships  between  measured  GFR and  MDRD GFR or  CG GFR are  depicted  in
Figures  2  and  3,  respectively.  As shown  in  Figures  2A and  3A,  standard  regression
analyses  of  these  relationships  showed  a  good  global  agreement  between  the  two
variables  (r = 0.910 and  0.894,  respectively).  However,  as extensively studied  by Bland
and  Altman,  the  measurement  of  agreement  between  two  methods  should  be
preferentially  expressed  using bias  plots  of the  difference  against  the  average  (27,  23,
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14,  4,  22).  Such a  plot  showed  a  mean  difference  of  - 0.99  mL/min/1.73m 2 between
MDRD GFR and  measured  GFR (Figure  2B),  which  corresponds  to  a  statistically
significant  (p  = 0.001)  but  rather  limited  bias  of  the  MDRD equation.  Similarly,  when
applied  to  CG GFR,  the  Bland  and  Altman  plot  showed  a  mean  difference  of  1.94
mL/min/1.73m 2 (Figure  3B),  which  is  highly  statistically  significant  (p  < 0.0001)  but
has  limited  clinical  implications.  However,  for  both  formulas,  the  biases  were  not
uniform  over  the  whole  range  of GFR values  (Table  2A).
The  performance  of  an  equation  largely  depends  on  its  precision.  The  standard
deviation  of  the  mean  difference  was  used  to  characterize  the  precision  of  each
equation.  It  was  13.7  and  15.4  mL/min/1.73m 2 for  the  MDRD and  CG formulas,
respectively.  However,  as observed  in Figures  2B and  3B, this lack of precision was not
identical  throughout  the  whole  range  of  GFR values,  and  both  formulas  were  much
more  precise  for  low GFR values.  This led  us to  analyze  the  precision  of each  formula
according  to  GFR levels  (Table  2A).  For  all  categories  of  GFR, the  MDRD formula  was
more  precise  than  the  CG one  (Table  2A).
Accuracy is a global  indicator  of the  performance  of a formula,  that  takes  into  account
its  bias  and  its  precision.  We tested  the  accuracy  of  both  formulas  in  subjects  with
measured  GFR higher  and  lower  than  60 mL/min/1.73m 2 by calculating  CRMSE and  by
determining  the  percentage  of subjects  not  deviating  from  more  than  15,  30 and  50%
from  measured  GFR (Accuracy  within  in  Table  2B).  In  all  cases,  and  with  both
measurements  of  accuracy,  the  MDRD formula  had  better  performances  than  the  CG
one  (Table  2B).
Since,  the  performance  of a  regression-based  equation  depends  on the  population  the
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equation  is applied  to,  we  tested  the  performance  of  the  equations  in  CKD patients
and  in  kidney  donors  (Table  3A and  3B).  We  also  assessed  the  sensitivity  and
specificity  of the  two  formulas  for  assigning CKD patients  to  the  categories  defined  by
the  KDOQI CKD classification  (Table  3A) (25).  Performance  of the  MDRD equation  was
slightly  but  not  significantly  better  in  kidney  donors  (Table  3B) than  in  stage  1 or  2
CKD patients  (Anova,  p = 0.49,  NS). The CG formula  was less biased  in stage  1 or 2 CKD
patients  than  in kidney donors  (Anova,  p = 0.001).  
3. Comparison of bias and precision of estimated GFR values according to gender and
age
Besides  plasma  creatinine  values,  gender,  age  and  weight  are  the  three  parameters
that  are  taken  into  account  in the  MDRD and/or  CG formulas.  We thus  analyzed  the
performance  of these  two  formulas  according to  age,  gender,  and  BMI. As a  first  step,
we focused  on gender  and  age,  since  these  parameters  are  used  in both  formulas.
Biases  of  the  MDRD and  CG formulas  with  respect  to  gender  and  in two  different  age
groups  are  shown  in Figure  4.  A cut- off  age  of  65 years  was  chosen,  since  data  from
the  United  States  Renal  Data  System  show  that  the  incident  rates  of  ESRD are  more
than  two- fold  higher  in subjects  65 years  or  older  than  in younger  ones  (32).  The  bias
of the  MDRD formula  was very small in all subgroups,  except  for female  under  65 years
of  age  (bias:  -3.1  ± 17.2  mL/min/1.73m 2),  while  the  biases  of  the  CG formula  were
always significantly  larger  (p < 0.0001).
The  precision,  and  accuracy  of  the  two  formulas  according  to  gender  and  age  are
reported  in  Table  4.  The  MDRD formula  was  more  precise  and  accurate  than  the  CG
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one  in all  subgroups  of  patients;  the  only exception  being  the  subgroup  of  female  65
years  or older  with  a measured  GFR <60 mL/min/1.73m 2.  
Another  approach  to  estimate  the  global  accuracy  of the  formulas  was  to  analyze  the
absolute  of  the  difference  between  estimated  and  measured  GFR values  (27,  23,  14,
4,  22).  It  was  expressed  both  in mL/min/1.73m 2 and  as  a  percentage  of  GFR values,
and  represented  in percentiles  (50 th,  75th,  and  90th),  to  allow the  drawing  of absolute
and  relative  boundaries  for  the  lack  of accuracy  (Figures  5A and  5B).  In all  cases,  the
MDRD formula  was  at  least  as  accurate  as  the  CG one.  The  CG formula  principally
lacked  accuracy  in  subjects  younger  than  65  years  and  with  GFR values  <60
mL/min/1.73m 2 while  the  accuracy  of  the  MDRD formula  was  much  more  uniform
(Figure  5B).
4.  Comparison  of  bias and precision  of  estimated  GFR values  according to  body
mass index
The  cohort  was  divided  into  four  standard  subgroups  according  to  body  mass  index
(BMI) values:  < 18.5  kg/m 2 (underweight,  94 subjects),  between  18.5  and  24.9  kg/m 2
(normal,  1,010 subjects),  between  25 and  29.9  kg/m 2 (overweight,  712 subjects)  and  ³
30  kg/m 2 (obese,  279  subjects).  ANOVA analysis  showed  that  each  BMI class  was
associated  with  statistically  different  GFR values  (55.1  ± 32.0,  64.3  ± 32.9,  60.9  ±
32.2,  and  52.2  ±  31.5  mL/min/1.73m 2 from  underweight  to  overweight  subjects,
respectively,  p  <  0.0001).  As  shown  in  figure  6,  the  MDRD formula  largely
overestimated  kidney  function  in  underweight  subjects;  the  bias  observed  for  this
subgroup  (12.2  ±  24.8  mL/min/1.73m 2)  being  significantly  higher  than  the  one
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observed  for  all  other  classes  of  BMI (p  <  0.0001  by  ANOVA test).  In  all  other
subgroups,  the  MDRD formula  was  less  biased,  more  precise  and  more  accurate  than
the  CG one  (Figure  6).
5.  Consequences  of  the  limitations  of  the  MDRD and Cockcroft  formulas  on the
K/DOQI CKD classification
The  K/DOQI guidelines  recommend  to  define  a  clinical  action  plan  for  each  patient
with  CKD, based  on  the  stage  of  disease  as  defined  by the  K/DOQI CKD classification
(25).  Therefore,  we  evaluated  the  consequences  of  the  limitations  of  the  MDRD and
CG formulas  on the  classification  of  CKD patients  (Table  5A).  This analysis  was  based
solely  on  results  of  GFR determinations  and  all  2,095  subjects  were  considered,
whether  or  not  they  had  kidney  damage.  For subjects  with  GFR ³  90 mL/min/1.73m 2,
the  CG formula  was  slightly  more  accurate  than  the  MDRD one,  but  for  all  other  GFR
levels,  more  subjects  were  classified  in the  proper  stage  by the  MDRD formula  than  by
the  CG one  (Table  5A). Overall,  only 70.8% and  67.6% of subjects  were  classified  in the
correct  stage  by the  MDRD and  CG formulas,  respectively.  Using the  average  values  of
both  formulas  to  estimate  GFR did  not  improve  the  accuracy  of the  prediction  (Table
5B).  The  consequences  of  the  limitations  of  the  formulas  can  also  be  depicted  by a
figure  plotting  prediction  intervals  of  measured  GFR as  a  function  of  estimated  GFR
(Figure  7).  
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DISCUSSION
In  this  study,  we  evaluated  the  performances  of  the  CG and  MDRD formulas  for
estimating  GFR,  in  a  cohort  of  2,095  subjects.  As recommended  by  the  K/DOQI
guidelines,  these  two  formulas  are  increasingly  used  in  daily  clinical  practice  and
decisions  regarding  the  care  of  CKD patients  are  based  on  estimated  GFR, but  their
accuracy  is still debated  (20).
An important  characteristics  of our  cohort  is that  it  included  subjects  whose  measured
GFR ranged  from 2.3  to  166.4  mL/min/1.73m 2 (IQR: 33.6  - 87.3  mL/min/1.73m 2),  with
similar  numbers  of  subjects  having  measured  GFR values  above  and  below  60
mL/min/1.73m 2 (1,044  and  1,051  subjects,  respectively).  Thus,  the  performances  of
the  CG and  MDRD formulas  could  be  assessed  over  a  wide  range  of  kidney  function.
Furthermore,  since  the  vast  majority  of patients  included  in this study were  Europeans
the  performances  of  the  MDRD and  CG formulas  could  be  assessed  in  a  group  of
subjects  whose  anthropometric  characteristics  are  slightly  different  from  those  of
Americans.  For example,  when  compared  to  the  MDRD cohort  (27,  23,  14,  4,  22),  the
mean  weight  of  our  study  population  was  11.2% lower  (70.7  ± 15.3  kg versus  79.6  ±
16.8  kg),  and  the  mean  body surface  area  was  6.3% lower  (1.79  ± 0.21  kg/m 2 versus
1.91 ± 0.23 kg/m 2),  while  on average  our patients  were  only 2.2  years  older  than  those
included  in the  MDRD cohort  (52.8  ± 16.5  years  versus  50.6  ± 12.7  years)  and  while  a
similar  percentage  of subjects  were  male  in both  cohorts  (59% versus 60%).
Recent  studies  have  emphasized  the  importance  of  careful  calibration  of  serum  creatinine
measurements to reliably estimate GFR in patients with normal or near normal renal function,
using creatinine-based equations (10, 9). In the absence of international standard, we have used
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plasma samples supplemented with precise amounts of creatinine hydrochloride to calibrate our
assay.  Analysis  of  the  relationship  between  expected  and  measured  creatinine  concentration
strongly suggests  that  our assay reliably measures  creatinine concentrations.  The relationship
between measured and expected creatinine concentrations was linear over a wide range of values,
and not different from the identity line. Furthermore, in our population, the ratio of MDRD GFR
over measured GFR did not vary over time, which suggests that no calibration bias occurred over
time. This careful calibration of plasma creatinine measurements may explain that, for subjects
with normal or near normal kidney function, we found much less differences between estimated
and measured GFR than in other studies (27, 23, 14, 4, 22).
In this study, GFR was measured by renal clearance of 51Cr-EDTA, while renal clearance of 125I-
iothalamate has been used by studies in North America. However, the performance of our method
is similar to what has been reported for iothalamate clearance (26).
Analysis of bias, a measure of systematic error, in the entire study population showed a very
good global agreement between estimated and measured GFR for each of the two formulas. On
average, estimated GFR was only 1.0 mL/min/1.73m2 lower than measured GFR with the MDRD
formula and 1.9 mL/min/1.73m2 higher with the CG formula. A similar bias has been observed
when  the  CG formula  was  compared  to  GFR  measured  by  125I-iothalamate  clearance  in  all
patients screened for  the AASK study;  the mean difference  between estimated and measured
GFR being –2.7 mL/min/1.73m2 (27, 23, 14, 4, 22). In contrast, in the MDRD cohort, the CG
formula was shown to largely overestimate measured GFR (19). The reasons for this discrepancy
are not clear, but it may be due to differences in patients characteristics. 
When estimating  the  performance  of a  formula,  precision  is probably  more  important
than  bias.  Our  study  showed  that  both  the  MDRD and  CG formulas  largely  lack
precision.  Previous  studies  focusing  on  patients  with  or  without  CKD have  already
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highlighted  the  global  lack  of  precision  of  these  two  formulas  (27,  23,  14,  4,  22).
However,  in our  analysis their  performances  were  quite  different  in various  subgroups
of subjects.  The greatest  lack of precision was observed  for subjects  less than  65 years
with  measured  GFR above  60 mL/min/1.73m 2,  for  underweight  subjects,  and,  in  the
case  of the  CG formula,  for obese  subjects.
Analysis of the  ability  of a  formula  to  classify patients  in different  subgroups  depends
on the  characteristics  of the  population.  In particular,  it  depends  on the  proportion  of
patients  who  happen  to  be  near  the  boundaries  of  the  subgroups.  In  our  series,
analysis  of  the  performance  of  both  formulas  to  classify  patients  according  to  the
K/DOQI CKD classification  showed  that  only 70.8% of  subjects  were  classified  in  the
proper  category  when  using  the  MDRD formula  and  67.6% when  using  the  CG one,
which clearly  highlights  the  limitations  of both  formulas.  For example,  when  using the
CG  and  the  MDRD formulas,  28.8%  and  16.7%  of  stage  4  CKD patients  were
misclassified  as  stage  3  CKD patients,  respectively,  which  could  introduce  undue
delays  in  the  preparation  for  renal  replacement  therapy.  By contrast,  about  20% of
subjects  with  measured  GFR ³  60  mL/min/1.73m 2 were  classified  as  having  stage  3
CKD with  both  formulas,  which  could  lead  to  unnecessary  assessment  of  CKD-related
complications.  Use  of  the  average  of  the  two  formulas  did  not  decrease  the
misclassification  rate,  which  answers  to  one  the  K/DOQI research  recommendations
(25).  In  order  not  to  be  misled  by  the  use  of  the  formulas  when  taking  care  of
individual  CKD patients,  it  is  probably  important  to  keep  in  mind  the  width  of  the
prediction  interval  for GFR associated  with  each  value  of estimated  GFR (Figure  7).  
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In conclusion,  in  a  study  population  of  2,095  European  subjects,  the  MDRD formula
provided  more  reliable  estimations  of kidney  function  than  the  CG formula.  However,
both  formulas  lacked  precision,  and  using either  one  of them  for  defining the  stage  of
disease  according  to  the  K/DOQI CKD classification  would  have  led  to  inappropriate
staging of about  30% of subjects.
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Table  1: Demographic  and clinical  characteristics  of study population.  Data  are  given as mean  ± SD (median  /  interquartile  range)
BSA: body surface  area;  BMI: body mass index
Overall Female  
(n = 863)
Male 
(n = 1,232)
(n = 2,095) Age < 65
(n = 630)
Age ³  65
(n = 233)
Age < 65
(n = 870)
Age ³  65
(n = 362)
Plasma  creatinine
(mg/dL)
1.69 ± 1.25
(1.24/0.91- 2.01)
1.29 ± 1.06
(0.91/0.75- 1.39)
1.58 ± 1.12
(1.22/0.89- 1.94)
1.79 ± 1.31
(1.31/0.97- 2.10)
2.22 ± 1.27
(1.77/1.31- 2.75)
GFR
(mL/min/1.73m2)
61.1 ± 32.7
(59.8/33.6- 87.3)
72.2 ± 34.1
(79.0/41.2- 97.6)
48.3 ± 26.0
(45.8/27.3- 64.2)
64.0  ± 32.5
(65.7/35.5- 90.0)
43.3  ± 22.9
(41.9/23.0- 60.4)
Age
(year)
52.8 ± 16.5
(53.2/40.2- 66.7)
43.5 ± 12.2
(44.8/34.8- 53.2)
72.9 ± 5.1
(73.0/68.7- 76.1)
46.0  ± 12.3
(47.9/36.6- 56.0)
72.5  ± 4.8
(72.2/68.3- 75.4)
Weight
(kg)
70.7 ± 15.3
(69.4/60.0- 80.0)
62.7 ± 15.0
(60.0/53.0- 69.2)
64.5 ± 11.1
(64.0/56.0- 72.0)
76.1  ± 14.1
(75.2/67.0- 84.3)
75.8  ± 13.2
(74.4/67.0- 82.6)
Height
(cm)
167 ± 9
(168/161- 174)
161 ± 7
(161/157- 166)
157 ± 6
(156/152- 160)
173 ± 7
(173/169- 178)
170 ± 7
(170/165- 174)
BSA 
(m2)
1.79 ± 0.21
(1.79/1.64- 1.93)
1.65 ± 0.18
(1.63/1.54- 1.75)
1.64 ± 0.14
(1.64/1.54- 1.74)
1.90 ± 0.18
(1.89/1.78- 2.01)
1.87 ± 0.17
(1.85/1.76- 1.97)
BMI
(kg/m 2)
25.2 ± 4.8
(24.7/22.0- 27.8)
24.1  ± 5.8
(22.8/20.6- 26.7)
26.3 ± 4.4
(26.2/23.0- 29.3)
25.3 ± 4.2
(25.0/22.5- 27.7)
26.2  ± 4.4
(25.8/23.8- 28.2)
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Table  2A: Bias and precision  of the  MDRD and CG formulas.  Results  obtained  with
these  formulas  were  compared  to  GFR values  obtained  by measuring the  renal
clearance  of 51Cr EDTA. The study population  was divided  into  five categories,
according to  the  GFR levels used  to  define  the  five stages  of CKD in the  K/DOQI CKD
classification  [NKF, 2002 #411].
Measured  GFR N MDRD formula
(mL/min/1.73m 2)
CG formula
(mL/min/1.73m 2)
(mL/min/1.73m
2)
Bias Precision Bias Precision
³  90 482 -6.2
(-5.3)
18.8
(17.3)
-0.3
(0.2)
22.7
(21.2)
60 - 89 576 -0.8
(-1.1)
15.1
(20.4)
0.9
(0.9)
15.9
(21.4)
30 - 59 597 0.6
(1.6)
9.5
(22.6)
2.6
(6.7)
10.9
(25.8)
15 - 29 312 2.3
(11.3)
7.2
(35.0)
4.9
(24.0)
8.0
(38.7)
< 15 128 2.4
(26.8)
5.1
(54.7)
5.2
(54.2)
5.3
(58.7)
Bias is defined  as the  mean  difference  between  Estimated  and  Measured  GFR.
Precision is one  standard  deviation  of bias.
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Table  2 B:  Bias,  precision,  and accuracy of the  MDRD and CG formulas .  Results  obtained  with  these  formulas  were
compared  to  GFR values  obtained  by measuring the  renal  clearance  of 51Cr EDTA.
N
Bland and  Altman
(mL/min/1.73m 2)
Accuracy within
(% of subjects)
CRMSE
(mL/min/1.73m 2)
Bias Precision 15% 30% 50%
MDRD formula
High GFR* 1,04
4
-3.3 17.2 61.3 92.4 98.8 17.5
Low GFR† 1,05
1
1.3 8.5 54.8 82.9 93.3 8.6
Overall 2,09
5
-1.0 13.7 58.0 87.2 96.0 13.8
CG formula
High GFR 1,04
4
0.4 19.4 56.1 88.0 97.4 19.4
Low GFR 1,05
1
3.5 9.7 41.2 69.0 85.2 10.3
Overall 2,09
5
1.9 15.4 48.7 78.5 91.3 15.5
*High GFR: measured  GFR ³  60 mL/min/1.73m 2,  †Low GFR: measured  GFR < 60 mL/min/1.73m 2
Bias is defined  as the  mean  difference  between  Estimated  and  Measured  GFR.  Precision is one  standard  deviation  of bias.
Accuracy was assessed  by determining the  percentage  of subjects  not  deviating from more  than  15,  30 and  50% from
measured  GFR, and  by calculating  the  combined  root  mean  square  error  (CRMSE).
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Table  3A: Performances  of the  MDRD and CG formulas according to CKD classes  in CKD patients.  CKD patients  were
divided  into  five categories,  according to  the  GFR levels used  to  define  the  five stages  of CKD in the  K/DOQI CKD
classification  [NKF, 2002 #411].  Results  obtained  with  these  formulas  were  compared  to  GFR values  obtained  by measuring
the  renal  clearance  of 51Cr EDTA. Sensitivity and  specificity  of each  formula  for assigning patients  to  the  K/DOQI categories
of CKD as defined  by GFR was also analyzed.  
Measured  GFR N MDRD formula
(mL/min/1.73m 2)
CG formula
(mL/min/1.73m 2)
(mL/min/1.73m
2)
Bias Precision Sensitivity Specificity Bias Precision Sensitivity Specificity
³  90 370 -6.3 19.8 65.7 94.9 -1.4 24.0 69.2 93.5
60 - 89 526 -1.0 15.5 62.7 86.1 0.2 15.9 59.7 85.9
30 - 59 597 0.6 9.5 78.1 86.8 2.6 10.9 77.9 84.5
15 - 29 312 2.3 7.2 78.9 93.9 4.9 8.0 67.6 92.8
< 15 128 2.4 5.1 64.8 99.3 5.2 5.3 43.0 99.5
Bias is defined  as the  mean  difference  between  Estimated  and  Measured  GFR. Precision is one  standard  deviation  of bias.
Sensitivity is the  percentage  of well-classified  patients  within each  CKD class.
Specificity  is the  percentage  of patients  not  belonging to  the  CKD class of interest  that  are  not  classified  in this category  by
the  formula.
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Table  3 B: Performances  of the  MDRD and CG formulas according to CKD classes  in
kidney  donors.  Kidney donors  were  divided  into  two  categories,  according to  the  GFR
levels used  to  define  the  five stages  of CKD in the  K/DOQI CKD classification  [NKF,
2002 #411].  Results  obtained  with  these  formulas  were  compared  to  GFR values
obtained  by measuring the  renal  clearance  of 51Cr EDTA. 
Measured  GFR N MDRD formula
(mL/min/1.73m 2)
CG formula
(mL/min/1.73m 2)
(mL/min/1.73m
2)
Bias Precision Bias Precision
³  90 112 -5.8 15.3 3.3 17.3
60 - 89 50 0.6 11.5 8.3 14.3
Bias is defined  as the  mean  difference  between  Estimated  and  Measured  GFR.
Precision is one  standard  deviation  of bias.
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Table  4:  Performance  of the  MDRD and CG formulas according to gender,  age  and
GFR levels .  Data  are  presented  as bias (absolute  /  relative),  precision  (absolute  /
relative)   and  (CRMSE), all in mL/min/1.73m 2 or in %.
MDRD GFR CG GFR
Male Female Male Female
High GFR*
Age ≥ 65 yr. -5.9  /  -8.0
12.1 /  16.2
(13.5)
-1.6  /  -1.0
11.5  /  14.2
(11.6)
-14.5 /
-19.7
10.4  /  13.4
(17.9)
-10.7  /
-12.4
12.2  /  13.5
(16.2)
Age < 65 yr. -0.6  /  -0.2
16.4 /  18.6
(16.4)
-6.1  /  -5.4
19.3  /  20.7
(20.3)
3.2  /  4.1
17.1  /  19.2
(17.4)
2.5  /  3.7
22.2  /  22.7
(22.3)
Low GFR†
Age ≥ 65 yr. 0.5  /  5.6
6.7 /  31.4
(6.7)
1.2  /  7.6
8.2 /  34.1
(8.3)
-2.3  /  -0.2
7.2 /  32.0
(7.6)
-0.1  /  7.6
8.0 /  36.2
(8.0)
Age < 65 yr. 1.4  /  7.0
8.2 /  27.5
(8.3 )
2.3 /  10.5
10.7  /  41.6
(10.9 )
5.9 /  24.8
8.8 /  35.2
(10.6)
8.7  /  32.8
10.5  /  43.6
(13.6)
Overall -0.2  /  2.7
12.2 /  25.1
(12.2)
-2.2  /  1.5
15.6  /  30.6
(15.7)
1.5  /  8.0
13.7  /  30.7
(13.7)
2.5  /  10.7
17.6  /  34.5
(17.7)
*High GFR : ≥ 60 mL/min/1.73m 2,  †Low GFR :  < 60 mL/min/1.73m 2
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Table  5A: Classification  of  the  study population  according to  the  MDRD and CG formulas .  Measured  GFR was used  to
divide  the  study  population  into  five  categories  corresponding  the  five  stages  of  CKD in the  K/DOQI CKD classification
[NKF, 2002 #411].  For each  category,  the  subjects  were  then  reclassified  according  to  the  MDRD formula  and  to  the  CG
formula.  Numbers  in bold correspond  to  the  percentages  of subjects  who did not  change  stage  when  their  GFR level  was
estimated  using  a  creatinine- based  formula.  The  existence  of  kidney  damage  was  not  taken  into  account  for  this
analysis.
Subjects  with
measured  GFR
(mL/min/1.73m 2)
N Classification  based
on the  MDRD formula  
Classification  based
on the  CG formula
Stage
1
Stage
2
Stage
3
Stage
4
Stage
5
Stage
1
Stage
2
Stage
3
Stage
4
Stage
5
³ 90
(stage  1)
482 66.8% 32.6% 0.6% 0% 0% 72.2% 27.6% 0.2% 0% 0%
60 – 89
(stage  2)
576 15.6% 63.7% 20.5% 0.2% 0% 21.7% 58.7% 19.4% 0.2% 0%
30 – 59
(stage  3)
597 0.5% 11.9% 78.1% 9.5% 0% 0.5% 13.9% 77.9% 7.7% 0% 
15 – 29
(stage  4)
312 0% 0.3% 16.7% 78.8% 4.2% 0% 0.6% 28.8% 67.6% 2.9% 
< 15
(stage  5)
128 0% 0% 3.1% 32.0% 64.8% 0% 0% 3.1% 53.9% 43.0%
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Table  5B: Classification  of  the  study  population  according to  the  average  of  MDRD
and  CG formulas .  Measured  GFR was  used  to  divide  the  study  population  into  five
categories  corresponding the  five  stages  of CKD in the  K/DOQI CKD classification  [NKF,
2002 #411].  For  each  category,  the  subjects  were  then  reclassified  according  to  the
average  of MDRD and  CG formulas.  Numbers  in bold  correspond  to  the  percentages  of
subjects  who  did  not  change  stage  when  their  GFR level  was  estimated  using  a
creatinine- based  formula.  The existence  of kidney damage  was not  taken  into  account
for this analysis.
Subjects  with
measured  GFR
(mL/min/1.73m 2)
N Classification  based  on the  
average  of CG and  MDRD formulas  
Stage
1
Stage
2
Stage
3
Stage
4
Stage
5
³ 90
(stage  1)
482 69.5% 30.5% 0% 0% 0%
60 – 89
(stage  2)
576 17.9% 63.5% 18.4% 0.2% 0%
30 – 59
(stage  3)
597 0.3% 12.1% 80.1% 7.5% 0%
15 – 29
(stage  4)
312 0% 0.3% 22.1% 74.4% 3.2% 
< 15
(stage  5)
128 0% 0% 3.9% 40.6% 55.5%
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FIGURES  (figures  are  separately  submitted  as Tiff or eps  files)
Figure  1
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Figure  2
A B
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Figure  3
A B
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Figure  4
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Figure  5A
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Figure  5B
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Figure  6
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Figure  7
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LEGENDS TO FIGURES
Figure  1:  Relationship  between  theoretical  and  measured  plasma  creatinine
concentrations.  Increasing  amounts  of  desiccated  creatinine  hydrochloride  were  added  to
plasma  samples  drawn  from  normal  subjects;  creatinine  concentrations  were  measured.  The
measured  values  were  then  plotted  against  the  expected  values.  Solid  line  represents  the
linear  regression  relationship;  dashed  lines  represent  the  upper  and  lower  boundaries  of  the
95% confidence  interval  of the  slope  of the  relationship.
Figure  2:  (A) Relationship  between  measured  GFR and  MDRD GFR. (B) Bland and  Altman
plot  comparing  measured  GFR and MDRD GFR.  The  mean  difference  (M) is represented  by
the  dashed  line.
Figure  3:  (A) Relationship  between  measured  GFR and CG GFR. (B) Bland and Altman plot
comparing  measured  GFR and  CG GFR.  The  mean  difference  (M) is  represented  by  the
dashed  line.
Figure  4.  Representation  of  the  mean  difference  between  estimated  and measured  GFRs
in  the  study  population .  Mean  differences  are  shown  according  to  the  formula  used  to
estimate  GFR, and  to  age  groups and  gender.  
Figure  5:  Comparison  of  accuracy  of  the  MDRD (solid lines)  and CG (dashed  lines)  formulas
in  GFR prediction,  according  to  gender,  age,  and  measured  GFR levels  (high  GFR: ³  60
mL/min/1.73m 2,  low  GFR:  <  60  mL/min/1.73m 2).  (A)  Plotted  values  are  absolute  of
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difference  between  estimated  and  measured  GFR (expressed  in mL/min/1.73m 2).  (B) Plotted
values  are  absolute  of relative  error  between  estimated  and  measured  GFR (expressed  in %).
Figure  6: Representation  of the  mean  difference  between  estimated  and measured  GFRs
in the  study population .  Mean differences  are  shown according to  the  formula  used  to
estimate  GFR, and  to  BMI. The bars  in the  upper  part  of the  figure  represent  the  bias value  in
the  whole  population.  Precision is equal  to  the  standard  deviation  of the  mean  difference.  
Figure  7:  Predicted  values  of the  measured  GFR as a function  of the  estimated  GFR value
using the  MDRD formula.  Solid lines  represent  the  upper  and  lower  boundaries  of the  95%
confidence  interval  of the  measured  GRF values  for each  value  of estimated  GFR. Dotted  line
represents  the  mean  measured  GFR value  for each  value  of estimated  GFR.
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